Literature DB >> 25829985

The role of magnetic resonance imaging in management of patients with nonlobar hypertensive intracerebral hemorrhage.

Amir Adeli1, Réza Behrouz1.   

Abstract

BACKGROUND AND
PURPOSE: Despite the increased use and availability of magnetic resonance imaging (MRI), its role in hypertensive intracerebral hemorrhage (ICH) remains uncertain. In this retrospective study, we assessed the utility of MRI in diagnosis and management of patients with hypertensive ICH.
METHODS: We retrospectively reviewed the charts of patients with ICH presenting to our hospital over an 18-month period. We included patients who presented with hypertensive ICH in typical locations and excluded lobar hemorrhages. We further isolated cases that had undergone MRI. Collected data included mean age, gender, location of hematoma, neuroradiologist's interpretative report of the MRI, and management steps taken in response to the results of the MRI. Logistic regression was used to determine whether the overall yield of MRI in these patients was significant.
RESULTS: We found 222 patients with ICH in our database. Forty-eight patients met our inclusion criteria, of which 24 had brain MRI done as a part of their hospital workup. Brain MRI obtained in 2 (8%) of the 24 patients revealed abnormalities that led to a change in management. The diagnostic yield of MRI and the management decisions that followed were both insignificant.
CONCLUSIONS: The diagnostic yield of brain MRI in patients with nonlobar hypertensive ICH is low and does not result in significant changes in management.

Entities:  

Keywords:  hypertension; intracerebral hemorrhage; magnetic resonance imaging

Year:  2015        PMID: 25829985      PMCID: PMC4357601          DOI: 10.1177/1941874414561030

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  9 in total

Review 1.  Spontaneous intracerebral hemorrhage.

Authors:  A I Qureshi; S Tuhrim; J P Broderick; H H Batjer; H Hondo; D F Hanley
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

2.  MRI features of intracerebral hemorrhage within 2 hours from symptom onset.

Authors:  I Linfante; R H Llinas; L R Caplan; S Warach
Journal:  Stroke       Date:  1999-11       Impact factor: 7.914

3.  Utility of early MRI in the diagnosis and management of acute spontaneous intracerebral hemorrhage.

Authors:  Christine A C Wijman; Chitra Venkatasubramanian; Sara Bruins; Nancy Fischbein; Neil Schwartz
Journal:  Cerebrovasc Dis       Date:  2010-08-24       Impact factor: 2.762

4.  Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy.

Authors:  A Biffi; A Halpin; A Towfighi; A Gilson; K Busl; N Rost; E E Smith; M S Greenberg; J Rosand; A Viswanathan
Journal:  Neurology       Date:  2010-08-24       Impact factor: 9.910

5.  Use of antithrombotic agents in patients with intracerebral cavernous malformations.

Authors:  Kelly D Flemming; Michael J Link; Teresa J H Christianson; Robert D Brown
Journal:  J Neurosurg       Date:  2012-09-21       Impact factor: 5.115

6.  Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations.

Authors:  Hans-Martin Schneble; Aicha Soumare; Dominique Hervé; Damien Bresson; Jean-Pierre Guichard; Florence Riant; Elisabeth Tournier-Lasserve; Christophe Tzourio; Hugues Chabriat; Christian Stapf
Journal:  Stroke       Date:  2012-11-13       Impact factor: 7.914

7.  Hypertension as a risk factor for spontaneous intracerebral hemorrhage.

Authors:  T Brott; K Thalinger; V Hertzberg
Journal:  Stroke       Date:  1986 Nov-Dec       Impact factor: 7.914

Review 8.  Intracerebral haemorrhage.

Authors:  Adnan I Qureshi; A David Mendelow; Daniel F Hanley
Journal:  Lancet       Date:  2009-05-09       Impact factor: 79.321

9.  Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study.

Authors:  Meike W Vernooij; Mendel D M Haag; Aad van der Lugt; Albert Hofman; Gabriel P Krestin; Bruno H Stricker; Monique M B Breteler
Journal:  Arch Neurol       Date:  2009-04-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.